The Standing Paradox: How Mifepristone Returned to the Supreme Court Without an Injury

The Official Narrative

In 2026, the United States Supreme Court is hearing oral arguments in a second major challenge to the Food and Drug Administration's approval and regulation of mifepristone, the medication used in over half of all abortions in the United States. The case arrives two years after the Court unanimously dismissed the first mifepristone challenge, FDA v. Alliance for Hippocratic Medicine, in June 2024. In that decision, Justice Brett Kavanaugh wrote for a unanimous Court that the plaintiff physicians and medical associations lacked standing because they had not demonstrated a concrete injury traceable to the FDA's actions.

The new challenge features different plaintiffs—three states rather than individual physicians—asserting that the FDA's authorization of mifepristone imposes financial and administrative burdens on their healthcare systems. The states claim they must expend resources treating complications from medication abortion, and that federal approval of mifepristone by mail violates their sovereign interests in regulating medical practice.

The framing from these states is procedural: they have standing where the physicians did not because states possess special sovereign interests that individuals lack, and because they can point to concrete budget impacts. The Biden administration and FDA maintain that the states still fail the standing test because they have not shown the required causal connection between FDA approval and state expenditures, and because states cannot manufacture standing by choosing to regulate or subsidize activity they disapprove of.

The Constitutional Provision: Article III and the Case-or-Controversy Requirement

Article III, Section 2 of the Constitution extends federal judicial power only to "Cases" and "Controversies." This limitation is not procedural housekeeping—it is a structural safeguard against the federal judiciary becoming a roving commission to adjudicate abstract policy disputes. Since Lujan v. Defenders of Wildlife (1992), the Supreme Court has required plaintiffs to establish three elements: (1) a concrete and particularized injury in fact, (2) causation—a fairly traceable connection between the injury and the challenged conduct, and (3) redressability—a likelihood that the injury will be remedied by a favorable decision.

The standing doctrine exists to enforce separation of powers. As Justice Antonin Scalia wrote in Lujan, the requirement "preserves the vitality of the adversarial process" and prevents the judiciary from "usurp[ing] the powers of the political branches." When courts hear cases without genuine injury, they issue advisory opinions—exactly what Article III forbids.

In FDA v. Alliance for Hippocratic Medicine, the Court unanimously found that the physician plaintiffs could not establish injury because they were not the ones prescribed mifepristone, they did not prescribe it themselves, and federal conscience protections already exempted them from being compelled to participate in abortions. The decision was categorical: disagreement with federal policy, even deeply held moral disagreement, does not confer standing to sue.

What the Record Shows

The current case rests on a state-standing theory. States do occasionally receive more lenient treatment under standing doctrine—most notably in Massachusetts v. EPA (2007), where the Court recognized states' "special solicitude" in standing analysis when asserting quasi-sovereign interests. But that doctrine has strict limits. In Alfred L. Snapp & Son, Inc. v. Puerto Rico (1982), the Court clarified that states cannot manufacture standing by choosing to enforce or subsidize activity linked to a federal policy they dislike. A state must show harm to its sovereign interests, not merely increased costs from choosing to provide services.

The factual record reveals the gap. The states assert that mifepristone-related emergency room visits impose costs on state Medicaid programs and public hospitals. But mifepristone has a documented safety profile: FDA data and peer-reviewed research show serious adverse events occur in fewer than 0.3% of cases—a rate lower than many over-the-counter medications and far lower than complications from continued pregnancy or surgical abortion. The states have not demonstrated that FDA's regulatory decisions caused an increase in complications, nor that their expenditures would disappear if mifepristone were withdrawn.

More fundamentally, the states' theory collapses causation and redressability. Even if mifepristone were removed from the market, abortions would continue through other means—including surgical procedures and medications obtained outside FDA-regulated channels. The states' alleged injury is not the existence of FDA-approved mifepristone; it is the existence of abortion itself and the states' decision to provide healthcare coverage for complications. The causal chain is too attenuated and dependent on third-party decisions to satisfy Article III.

The Gap: What the States' Theory Omits

The states' standing argument omits a critical structural fact: if accepted, it would authorize any state to challenge any federal approval of any drug, device, or product that might generate healthcare costs within its borders. A state could sue over FDA approval of tobacco products, alcohol, high-risk sports equipment, or experimental medications—claiming each generates emergency room visits and Medicaid expenses.

This is not hypothetical concern-trolling. It is the logical terminus of the theory. The standing doctrine exists precisely to prevent such universal licenses to sue. The Supreme Court has repeatedly held that "generalized grievance[s]" shared by all citizens—or in this case, all states—do not satisfy Article III. Lujan foreclosed the argument that widely shared policy objections can be repackaged as concrete injuries through creative accounting.

The states' invocation of "quasi-sovereign interests" is similarly incomplete. Massachusetts v. EPA granted special solicitude to Massachusetts because the state alleged a particularized injury—rising sea levels threatening state-owned coastal land—not merely a policy disagreement with federal environmental standards. The mifepristone challengers identify no comparable sovereign interest. The regulation of medical practice within state borders is not threatened by federal drug approval; states remain free to regulate how medications are prescribed and dispensed, subject only to the limits the Supremacy Clause has always imposed.

What the Gap Reveals

The gap between the standing doctrine articulated in Alliance for Hippocratic Medicine and the acceptance of this second case reveals a structural ambiguity in how federal courts police their own jurisdictional boundaries. After a unanimous Supreme Court decision dismissing the first challenge for lack of standing, a second challenge with a nearly identical substantive claim but a reshuffled plaintiff lineup has reached oral argument.

This outcome suggests one of three possibilities. First, lower federal courts may be interpreting Massachusetts v. EPA as creating a broad state-standing exception that swallows the general rule—a reading the Supreme Court has not endorsed and that contradicts decades of precedent. Second, the Supreme Court may be using the case to clarify or narrow state standing, though granting certiorari rather than summarily dismissing suggests at least four justices see a question worth hearing. Third, the Court may be signaling that standing doctrine is now selectively enforced based on the substantive stakes of the dispute—a development that would undermine the structural purpose of Article III's limits.

The Structural Accountability Question

The mechanism for correcting this gap is internal to the judiciary: the Supreme Court can reaffirm that standing requirements apply with equal force to states as to individuals when the alleged injury is financial cost resulting from policy disagreement. The Court can clarify that Massachusetts v. EPA does not authorize states to manufacture standing through budget appropriations, and that quasi-sovereign interests do not include a general interest in objecting to federal regulatory decisions.

If the Court instead finds standing in this case, it will have created a two-track standing doctrine: one for plaintiffs challenging policies the Court views as routine, and another for plaintiffs challenging policies implicating contested constitutional rights. That outcome would convert Article III's case-or-controversy requirement from a structural safeguard into a discretionary filter—precisely what the Framers designed it not to be.

The question is not whether states should be able to restrict abortion or challenge FDA decisions through political channels—those avenues remain fully available. The question is whether the federal judiciary will enforce its own constitutional boundaries, or whether those boundaries dissolve when the policy stakes are high enough.